company background image
0JBU logo

Intellia Therapeutics LSE:0JBU Stock Report

Last Price

US$16.13

Market Cap

US$1.6b

7D

13.5%

1Y

-35.9%

Updated

07 Nov, 2024

Data

Company Financials +

Intellia Therapeutics, Inc.

LSE:0JBU Stock Report

Market Cap: US$1.6b

Intellia Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Intellia Therapeutics
Historical stock prices
Current Share PriceUS$16.13
52 Week HighUS$34.87
52 Week LowUS$13.98
Beta1.76
11 Month Change-8.25%
3 Month Change-25.32%
1 Year Change-35.90%
33 Year Change-87.57%
5 Year Change24.36%
Change since IPO-34.72%

Recent News & Updates

Recent updates

Shareholder Returns

0JBUGB BiotechsGB Market
7D13.5%-3.5%-0.3%
1Y-35.9%-16.7%8.7%

Return vs Industry: 0JBU underperformed the UK Biotechs industry which returned -16.7% over the past year.

Return vs Market: 0JBU underperformed the UK Market which returned 8.7% over the past year.

Price Volatility

Is 0JBU's price volatile compared to industry and market?
0JBU volatility
0JBU Average Weekly Movement9.6%
Biotechs Industry Average Movement8.8%
Market Average Movement4.6%
10% most volatile stocks in GB Market9.6%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0JBU's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0JBU's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2014526John Leonardwww.intelliatx.com

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.

Intellia Therapeutics, Inc. Fundamentals Summary

How do Intellia Therapeutics's earnings and revenue compare to its market cap?
0JBU fundamental statistics
Market capUS$1.63b
Earnings (TTM)-US$508.80m
Revenue (TTM)US$45.97m

35.5x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JBU income statement (TTM)
RevenueUS$45.97m
Cost of RevenueUS$448.73m
Gross Profit-US$402.76m
Other ExpensesUS$106.03m
Earnings-US$508.80m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)-5.01
Gross Margin-876.20%
Net Profit Margin-1,106.87%
Debt/Equity Ratio0%

How did 0JBU perform over the long term?

See historical performance and comparison